GTx/Merck SARM Demonstrates Muscle Improvements In Cancer Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II trial evaluating Ostarine in patients with cancer-induced muscle loss meets its primary endpoint.